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Introduction. Post-prostatectomy erectile dysfunction aﬀects a considerable number of men and is a signiﬁcant quality of life
issue. There has been a substantial amount of research on the treatment of post-prostatectomy ED, and now there is a rising
interest in the concept of penile rehabilitation. The goal of penile rehabilitation is to moderate the destructive processes that occur
after prostatectomy in order to preserve erectile function, either through spontaneous or assisted means. Methods. We reviewed
published data and experiences of post-prostatectomy penile rehabilitation using regimented interventions of phosphodiesterase
inhibitors, vacuum erectile device, and intracavernosal agents, and we present and analyze the research conducted. Results.T h e s e
studiesshowimprovedobjectiveandsubjectiveclinicaloutcomesinregardstophysicalparameters,sexualsatisfaction,andratesof
spontaneouserections.Conclusion.Thesestudiesareoftenlimitedbysmallsize,studyperiod,andstudydesign.Therecontinuesto
beaneedforlarge,randomized,placebocontrolledtrialswithadequatefollowuptofullyevaluatetheeﬃcacyandcost-eﬀectiveness
of the various proposed penile rehabilitation regiments before a clear standard can be established.
Copyright © 2008 P. Hinh and R. Wang. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Erectile dysfunction following prostatectomy remains a
signiﬁcant quality of life issue for men undergoing prosta-
tectomy.It is estimated to aﬀect 26–100% of patients after
surgery [1]. Even with advancements in understanding the
anatomy of the prostate and the neurovascular bundle [2], a
considerable number of men undergoing prostatectomy will
have resulting erectile dysfunction.
Progress has been made in identifying the events that
contribute to erectile dysfunction after prostatectomy. The
changes of neuropraxia, ischemic and hypoxic insults,
ﬁbrotic remodeling, and apoptosis are all believed to con-
tribute to erectile dysfunction [3, 4]. These events can
occur even in attempts at meticulous dissection to preserve
the neurovascular bundle. The etiologies of cavernous
nerve neuropraxia include mechanical stretch injury during
retraction, ischemia from accessory vessel disruption in
dissection, thermal injury from electrocautery use, and
inﬂammation from surgical trauma. This neuropraxia can
prevent erections, and the perpetual lack of erection can
itself set up a cascade of deleterious processes. Chronic
impotence reduces blood ﬂow to the corporeal bodies, which
leadstoﬁbrosisandtransformationofthetrabecularsmooth
muscle through collagen [5]. Further hypoxic insults also
may trigger apoptosis [6]. Therefore, the goal of penile
rehabilitation is to set up an environment that moderates
these processes in attempt of preserving penile function and
earlier return of potency. Regimented usage of erectile aids
aims to improve the circulation of oxygen and maintain the
structure of the corporeal bodies.
However, the research has yet to be translated into
a coherent clinical strategy for penile rehabilitation. As
such, there are no currently accepted guidelines for penile
rehabilitation regiments. Certainly, there exist several pop-
ular options that are currently in use. In practice, three
principle modalities of treating post-prostatectomy erectile
dysfunction are employed. This paper will review the eﬃcacy
of these options in this patient population for the purposes
of penile rehabilitation.
2. PHOSPHODIESTERASE 5 INHIBITORS
The introduction of phosphodiesterase inhibitors (PDEi)
revolutionized the treatment of erectile dysfunction. Since
entering the market in 1998, these medications have become2 Advances in Urology
Table 1: Summary table of penile rehabilitation trials.
Authors Year published Treatment regiment Study design N Signiﬁcant ﬁndings
Schwartz et al. 2004 QOD PDEi Prospective 21
No loss of smooth muscle in
50mg group, gain of smooth
muscle in 100mg group
Bannowski et al. 2008 Daily PDEi Prospective, randomized
control
41
Treatment group had
signiﬁcantly higher IIEF and
higher spontaneous erection
rates
McCullough et al. 2008 Daily PDEi Prospective, randomized,
placebo control
54
Treatment groups had higher
return of rigidity, higher rate of
spontaneous erections
Raina et al. 2006 Daily VED Prospective, randomized
control
109
Improved sexual satisfaction,
higher rate of spontaneous
erections
K¨ ohler et al. 2007 Daily VED (10mins),
immediate versus delayed Prospective, randomized 28
Delayed use of VED did not
aﬀect sexual satisfaction once use
began. There is no statistical
signiﬁcance in penile shrinkage
once VED started
Montorsi et al. 1999 ICI 3 times weekly Prospective, randomized
control
30
Higher percentage of treatment
group having spontaneous
erections
Mulhall et al. 2005 I C Io rP D E it oa c h i e v e
erections 3 times weekly Prospective, control 132
Treatment groups had 2.7 times
the rate of spontaneous
erections, statistically higher IIEF
scores
Nandipati et al. 2006 Daily PDEi and ICI 2-3
times week Prospective 22
Assisted early sexual activity and
satisfaction. Addition of PDEi
allows lower dose of ICI.
nearly synonymous with erectile dysfunction. Their ease of
use and relatively safe proﬁle have made them pervasive in
the treatment of erectile dysfunction. They have also been
extensively investigated. A Cochrane meta-analysis looking
atmanylarge,randomizedclinicaltrialsconcludedthatPDEi
are eﬃcacious in the treatment of erectile dysfunction and
are generally safe [7]. However, their role and their admin-
istration in penile rehabilitation after prostatectomy remain
undeﬁned. A number of clinical studies have investigated
PDEi use in this population for this intention.
One of the ﬁrst studies on PDEi in rehabilitation
looked at objective data to support this use. Schwartz et al.
conducted a study on 40 men who had undergone nerve
sparing prostatectomy [8]. Prior to prostatectomy, all men
had percutaneous biopsy of cavernous tissue to serve as
baseline reference. They were divided into receiving either
50 or 100mg of Sildenaﬁl every other night. Participant
then underwent percutaneous biopsy of cavernous tissue
at 6 months to compare with baseline tissue. Investigators
found that the 50mg group did not experience any loss
of smooth muscle compared with baseline, and the 100mg
group actually showed an increase of smooth muscle content
when compared to the baseline. There was no control
group, and no clinical correlation between smooth muscle
preservation and erectile function is made in this study.
A prior animal study had shown that cavernosal smooth
muscle does atrophy after prostatatectomy [9], though this
eﬀect is somewhat mediated with unilateral nerve sparing
anditisuncleartowhatextentthisatrophywouldoccurwith
nerve sparing prostatectomy.
Bannowski et al. conducted a randomized trial following
43 men who underwent nerve-sparing radical prostatectomy
[10]. All men provided baseline International Index of Erec-
tile Function (IIEF) scores prior to surgery. After catheter
removal following surgery, the men underwent testing for
nocturnal tumescence the following evening measured by
the rigiscan. 41 of 43 were found to have spontaneous
erections on rigiscan, and these men were then randomized
to receive sildenaﬁl daily or no treatment. They were then
followed and evaluated with IIEF at 6, 12, 24, 36, and 52
weeks. The results show that the daily treatment group
had signiﬁcantly higher IIEF score by 36 and 52 weeks.
Additionally, 47% of the daily treatment groups were able
to achieve spontaneous, unassisted erection suﬃcient for
penetration. This compares to 28% of the control group
w h ow e r ea b l et oh a v es u c he r e c t i o n s .B o t hg r o u p sw e r e
also allowed Sildenaﬁl on demand, and accounting assisted
erections, 86% of the daily group had erections suﬃcient
for penetration, compared to 66% of the control group. The
study made no mention of any participant drop out, andP. Hinh and R. Wang 3
there was no placebo control. However, it does appear that
dailySildenaﬁldoesimprovereturnofspontaneouserections
and can augment response to on-demand use of Sildenaﬁl.
A stringent, randomized, double-blinded, placebo con-
trolled studywas performed by McCullough et al. evaluating
the eﬃcacy of daily Sildenaﬁl in men after bilateral nerve-
sparing radical prostatectomy [11]. This study included
54 men with baseline normal EF and NPTR (nocturnal
penile tumescence and rigidity with duration of rigidity
>55% of maximal rigidity using penile plethysmography).
After a pretreatment period of 4 weeks, they were then
randomized to either receive nightly 100mg Sildenaﬁl (N =
18), 50mg Sildenaﬁl (N = 17), or placebo (N = 19).
The groups were then analyzed at 16, 28, and 40 weeks.
Then after 40 weeks, all medications were discontinued
and the groups were again analyzed at 48 weeks. At each
point, the participants were evaluated by NPTR and IIEF .
The study found that the groups receiving daily Sildenaﬁl
were able to have return of rigidity (R>55%) at seven
times the nadir value compared to minimal improvement
in the control group. This improvement of erection was
also seen by the investigators for RAU (rigidity-activated
unit—a time-intensity measurement that represents the area
under the rigidity curve during a qualiﬁed event), with
the additional ﬁnding that the 100mg group experienced
continued improvement after the discontinuation phase,
while the 50mg group began to experience decline in RAU.
Importantly,themenondailySildenaﬁlwereﬁvetimesmore
likely to have return of spontaneous, unassisted erection
suﬃcient for intercourse compared to placebo. The authors
were able to link objective measurements of erections with
subjective, clinical response. They noted that tip rigidity
>55% clearly separated responders versus nonresponders
(responders deﬁned as recovery of spontaneous, unassisted
suﬃcient erections). This study may mark objective vali-
dation as an important component of future clinical trials.
These initial results are from a subset analysis performed on
men who showed normal EF and NPTR on baseline, and we
await further data and analysis on the entire study patients.
Taken together, these studies seem to indicate that
phosphodiesteraseinhibitors have a role in penile rehabil-
itation for men after prostatectomy. There may also be a
dose-dependent relationship between the medication and
outcomes. The studies also conﬁrm the tolerability and
safety of such a regiment, as discontinuation rates were very
minimal and no adverse events were reported.
3. VACUUM ERECTILE DEVICE
The Vacuum erectile device assists erections by drawing
blood ﬂow into the cavernous sinuses through negative
pressure, physically causing an erection. A constrictive band
can also be placed at the base of the penis, preventing
backﬂow and maintaining corporal pressures. This direct
mechanism of action can circumvent the limitation of oral
agents, which requires an intact and functioning neuronal
connection to produce erections. This can be a signiﬁcant
factor even in men undergoing nerve sparing prostatate-
ctomy, as neuropraxia still occurs and can diminish the
eﬀectiveness of PDEi.
This treatment modality can also be extended to
men who have undergone nonnerve sparing prostatectomy,
though not in the context, in penile rehabilitation with the
e x p e c t a t i o no fr e t u r no fp o t e n c y .
If not for potency itself, VED usage has also been
advocated due to its possible eﬃcacy in preventing penile
shrinkage and maintaining length. Studies have shown
signiﬁcant shrinkage of penile length, with one study ﬁnding
that nearly 20% of men experience a loss of length greater
than 15% [12]. In another study examining penile short-
ening after prostatectomy, Gontero et al. followed 126 men
who had undergone prostatectomies and measured penile
length prior to surgery, at the time of catheter removal,
and then at 3, 6, and 12 months [13]. They found that
the greatest amount of shrinkage occurs in the immediate
postoperativeperiod,thoughshorteningcontinuesatalesser
rate throughout the entire study period. These authors
hypothesize that early hypoxia leads to increased expression
of TGF-B and Collagen I and III ﬁbers. This study also ﬁnds
that the return of erectile function, deﬁned as an IIEF of
15, was associated with mitigation of the shrinkage, as well
as having a nerve sparing surgery. Several studies looking at
the eﬃcacy of vacuum erectile device in preserving erectile
function have also examined preserved penile length as a
secondary endpoint.
Raina et al. randomized 109 post-prostatectomy men to
eitherearlyVEDusedaily(N = 74)versusnoerectogenicaid
(N = 35) [14]. The men were to use the constriction band
only during intercourse to maintain rigidity. Participants
were followed with SHIM and IIEF scores for comparison.
For the group using VED, 80% were able to achieve pene-
tration with use of VED, and this group, not surprisingly,
had a signiﬁcantly higher SHIM and IIEF group compared
to no treatment. The discontinuation rate was 18%, and
the majority of the drop out was for discomfort. In the
context of penile rehabilitation, at 9 months this study found
that 17% of those adhering to daily VED were able to have
spontaneous erections suﬃcient for erections at 9 months,
compared to 11% (n = 4) of the control group that had such
erections. In regard of the eﬀect of VED on penile length,
the men who adhered to VED regiment experienced less
subjective penile shrinkage, with 23% reporting less length
compared to 85% of the men who quit treatment and 65%
of the control. No objective data was collected concerning
length. The authors conclude that early use of VED with the
purpose of penile rehabilitation improves sexual and partner
satisfaction and allow for earlier return of spontaneous
erections. Although, the rate of return of spontaneous
erection is low for both groups, those numbers include
men who had undergone nonnerve sparing prostatectomies.
This distinction is necessary, as penile rehabilitation is more
directed for NS men and the inclusion of nonnerve sparing
prostatectomypatientsdilutedtheresponsetorehabilitation.
The timing of when to initiate VED has been questioned,
with some advocating an earlier intervention. K¨ ohler et al.
randomized 28 men to either receive early VED regiment (1
month after RP) or delayed VED regiment (6 months) [15].4 Advances in Urology
The regiment consisted of 10 minutes of VED usage without
the constriction band. IIEF was measured at baseline, 1, 3,
6, 9, and 12 months. The mean followup was 9.5 months
and the results analyzed at 3 and 6 months showed that
the early interventiongroup had a statistically higher IIEF
score. At this point, the comparison shows that VED does
improve IIEF scores among those who use VED versus those
controls that do not. At beyond 6 months, the delayed group
began using of VED, and at short followed up the two groups
converged with no statistical diﬀerence in IIEF categoriza-
tion. No patients in this study had return of spontaneous
erections suﬃcient for penetration at that followup. This
paper was presented as a pilot study, and more outcomes
are expected to follow, especially data concerning return
of spontaneous erections. There are still some important
points that can be gleamed from this study. For one, the
authors reported complete compliance with this regiment,
suggestingthisshortregiment(twoﬁve-minutecycles)could
be feasibly implemented. Importantly, these researchers also
looked at penile length and found that the group performing
VED regiment did not experience penile shrinkage, while the
group on delayed VED showed signiﬁcant penile shrinkage
at 3 (mean loss 1.87cm) and 6 months (mean 1.82cm).
However, after beginning VED in the delayed group, the
loss decreased to a mean of 1cm and no longer remained
statistically signiﬁcant. Again, this is short-term followup
data in the delayed group, and further improvement in
shrinkage may still yet be seen. We still await data concerning
return of spontaneous erection from this study.
The value of VED in penile rehabilitation remains
uncertain.DailyregimenteduseofVEDrequiresamotivated
patient and does improve sexual satisfaction in those who
responds. If the stated goal of penile rehabilitation is the
returnofpreexistingpotency,thenfurtherstudiesareneeded
to show that VED improves the rate of return of erection.
However, VED use may also be advocated for its eﬀects on
preventing penile shrinkage after prostatectomy.
4. INTRACORPOREAL INJECTION
Intracorporeal injection of vasoactive agents increase blood
ﬂow into the cavernous sinuses locally, either through
increasing cAMP, by antagonizing alpha-adrenergic recep-
tors, or by direct smooth muscle relaxation. Like VED, they
also do not require an intact, functional nervous system to
produceerections.Thus,theycanalsobeoﬀeredinmenwho
have undergone nonnerve sparing surgery and men who do
not respond to oral agents.
Montorsi et al. conducted a randomized trial inves-
tigating whether a regiment of intracavernosal injections
improves erectile function in post-prostatectomy men [16].
30 men with established preoperative potency were ran-
domized to either receive a regiment of 3 times per week
injections of alprostadil for 12 weeks versus a control group
that did not receive erectogenic treatment. The groups were
then assessed after 3 months for sexual history, for Doppler
response after alprostadil administration, and for nocturnal
tumescence. Of the ICI regiment group, 80% completed the
12 weeks of treatment with a 20% drop-out rate and a 17%
complication rate. Of these men, 67% at 3 months were
able to have spontaneous erections suﬃcient for penetration.
This favorably compares to 20% of the control group men
that were able to have such erections. The authors do note
that in this group some still continued to use ICI to achieve
erections. However, the authors considered it a complete
response since the majority of sexual encounters occurred
without ICI use (average of one in 4.2 attempts). The study
also found that having normal penile hemodynamics was
strongly associated with ICI complete response. The study
suﬀers from small size and short followup. However, it was
still able to show an improvement in spontaneous erections
for regimented ICI and that regimented ICI is generally well
tolerated.
Mulhall et al. conducted a trial that may be more
clinically applicable, even though it was not randomized
[17]. In this trial, post-prostatectomy men were committed
to penile rehabilitation with Sildenaﬁl or ICI if there was
no response to Sildenaﬁl, versus no penile rehabilitation
program, but they were not restricted from using erectile
aids. The rehabilitation group used either Sildenaﬁl or ICI
three times per week. Analysis at 18 months revealed that
52% of rehabilitation men were able to have functional
erections,comparedto19%ofcontrolgroupmen.Addition-
ally, the rehabilitation group had signiﬁcantly higher IIEF
scores. These results are impressive, especially considering
that the control group was also able to use erectile aids,
including both Sildenaﬁl and ICI, though not in a regi-
mented manner. The study included men with nonnerve
sparing prostatectomies, which generally are not considered
candidates for erectile rehabilitation, though the authors do
note that there was not a diﬀerential distribution between
the groups. Additionally, the average length of time before
sexual consultation and therefore the start of rehabilitation
were 4.2 months. Some would suggest that this length of
time is too long removed from the surgery, and the insults of
hypoxia, ﬁbrosis, and apoptosis may have already occurred
and be irreversible at this point. It is also important to note
that selection bias may be very considerable in this study, in
that only men who prospectively committed themselves were
included in the rehabilitation group and the study relied on
mainly self-reported, subjective data.
5. COMBINATION THERAPIES
Studies have examined the feasibility and eﬃcacy of employ-
ing two treatment modalities during penile rehabilitation.
Nandipati et al. incorporated both intracavernosal therapy
andPDEiinagroupof22menwhounderwentnervesparing
prostatectomy[18].AllparticipantsreceivedSildenaﬁl50mg
daily (25mg if subjects complained of headaches). For ICI,
18 patients received PGE 1–4 micrograms and 4 received
trimix injection, with ICI being done two to three times per
week. These patients were then analyzed at 3, 6, 9, and 12
months with IIEF . Doppler studies were performed for dose
optimizations of ICI and at intervals to increase dosage for
response.Thestudyreportedameanfollowupofsixmonths.
At this point, investigators found that 21 of 22 patients were
sexually active, while 12 of the 21 were using ICI alone andP. Hinh and R. Wang 5
9 of 21 were using combination therapy. Of the 18 patients
using PGE, 12 were able to lower their dosage; while 1 of
the 4 patients on trimix was able to do so. 11 of the 22 men
had return of spontaneous erection, though none graded the
erections suﬃcient for penetration. The authors concluded
thattheadditionofSildenaﬁlcouldreducetheamountofICI
necessary to achieve erections. This study had a lower rate
of return of functional erections compared to other studies
looking at nightly PDEi 1 [11] or regimented ICI alone [16],
and this diﬀerence may be explained by the shorter followup
and the small number of participants. Without proper study
design, in such combination therapy studies, it is diﬃcult to
assign particular ﬁndings to speciﬁc intervention.
6. NOVEL THERAPIES
Othertherapiesoutsideofthesethreemainstreammodalities
have been investigated for penile rehabilitation after prosta-
tectomy. Recently, investigators in Korea looked at statins for
treating erectile dysfunction after prostatectomy [19]. The
basis for this hypothesis stems from the known protective
eﬀect on vascular endothelium and increased NO activity.
The researchers randomized 50 men post-prostatectomy to
receive 10mg of atorvastatin for 90 days. All men were then
to use Sildenaﬁl 50mg per day on demand. The men all
had superior function prior to the surgery with IIEF 25.
At 6 months of followup, the study found that the statin
group had more patients categorized at potent ( IIEF greater
than 16) with 11 in the statin group and 6 in the control
group. Additionally, more men in the statin group were able
to achieve vaginal penetration without PDEi than in the
control group (8 versus 4), though this signiﬁcance did not
reach statistical signiﬁcance. The study was neither blinded
nor placebo-controlled. It is important to note that the
inclusion criteria were extremely stringent,and patients with
signiﬁcant cormidities were excluded. This may aﬀect the
applicability or generalizability of the results.
7. CONCLUSION
Sexual potency after prostatectomy remains a signiﬁcant
quality of life issue after prostatectomy. There exist many
studies on the eﬃcacy of the various treatment options on
this patient population. There are much less data looking
on the eﬀects of regimented usage of PDEi, VED, and/or
ICI in improving erectile function in this group, and no
guidelines exist to help steer the clinician. We are still in
need of large, randomized, controlled, clinical trial with
adequate, long-term followup to evaluate this question.
Moreover, even after each treatment can be established to
be eﬃcacious in penile rehabilitation, the exact regiment
amount and duration will still be open to further inves-
tigations for optimization. This is a especially important
questionindealingwithphosphodiesteraseinhibitors,where
the cost of treatment is substantial. However, even though
currently sparse, the consistent, growing body of evidence
does support penile rehabilitation in improving return of
sexual functioning. As awareness of penile rehabilitation
increases and becomes more accepted, it is becoming more
diﬃcult to conduct placebo or nonintervention controlled
trial.There are still several ongoing trials evaluating penile
rehabilitation, including a large multicenter study examining
penile rehabilitation with medicated urethral system for
erection (MUSE), and several of the studies presented here
will further analyze with additional data from which the
urology community may further deﬁne when and how to
implement penile rehabilitation in post-prostatectomy men.
Currently, the body of evidence does seem to suggest a
beneﬁcialroleforpenilerehabilitationafterprostatectomyin
improving return ofpotency. Such a program should begin
with a detailed evaluation on the preoperative sexual per-
formance characteristic of the patient and then a thorough
discussion of the available rehabilitation regiments. The
practitionershouldconsiderfactorsthatareimportanttothe
patient including ease of use and compliance, patient moti-
vation, conditioning, cost and patient expectations about
sexual function, and penile length. Penile rehabilitation may
continue to remain investigative until more standardized
clinical data becomes available.
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